

OPEN ACCESS

EDITED AND REVIEWED BY Giovanna Suzzi, University of Teramo, Italy

*CORRESPONDENCE Lili Sheng ⊠ llsheng@shutcm.edu.cn

RECEIVED 18 July 2023 ACCEPTED 25 July 2023 PUBLISHED 14 August 2023

CITATION

Sheng L, Zheng X, Shi L and Jena PK (2023) Editorial: Targeting gut microbiota modulation by dietary supplementation to improve metabolic diseases. *Front. Microbiol.* 14:1260520. doi: 10.3389/fmicb.2023.1260520

COPYRIGHT

© 2023 Sheng, Zheng, Shi and Jena. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Targeting gut microbiota modulation by dietary supplementation to improve metabolic diseases

Lili Sheng^{1*}, Xiaojiao Zheng², Lin Shi³ and Prasant Kumar Jena⁴

¹School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ²Center for Translational Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³College of Food Engineering and Nutritional Science, Shaanxi Normal University, Xi'an, China, ⁴Department Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, United States

KEYWORDS

diet, gut microbiota, NAFLD, metabolism, probiotic

Editorial on the Research Topic

Targeting gut microbiota modulation by dietary supplementation to improve metabolic diseases

Human gut microbiota is a complex and dynamic ecosystem, which is colonized by trillions of microorganisms (de Vos et al., 2022). Gut microbiota contributes to various physiological processes, such as immune maturation and homeostasis, protecting against pathogen overgrowth, regulating intestinal endocrine functions and neurologic signaling, modulating energy metabolism, and producing functional metabolites (Cani et al., 2019). Emerging evidence shows an altered gut microbiota composition and function in patients with various health issues including metabolic diseases (Wu et al., 2021). Animal studies further confirmed a causal role of gut microbiota in metabolic disorders, such as non-alcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes mellitus (T2DM) (Sung et al., 2017; Li et al., 2023). Diet is a key modifiable factor affecting the composition and function of the gut microbiota. Thus, gut microbiota-targeted therapies, such as diet supplementation with nutrients, probiotics, prebiotics, and natural compounds, might be a promising approach to counteract the dysbiosis-related deleterious consequences.

In this Research Topic, recent findings in the modulation of gut microbiota for alleviating NAFLD as well as the compositional and functional changes of gut microbiota during the improvement of certain health issues are highlighted. It comprised six studies: the roles of vitamin D (VD) (Zhang et al.) and *Lactobacillus plantarum* in alleviating NAFLD via regulating gut microbiota (Wen et al.), the effect of Roux-en-Y gastric bypass (RYGB) for weight loss on modulating gut microbiota to amoxicillin/clavulanate perturbation (Endika et al.) were explored. In addition, the factor that affects seasonal differences in the intestinal flora was reported (Li et al.), and the effects of dietary and microbial nutrients on improving premature ovarian insufficiency (POI) were reviewed (Han et al.).

The study conducted by Zhang et al. aimed to investigate the effect of vitamin D on alleviating HFD-induced NAFLD. The study found that VD intake alleviated the HFD-induced NAFLD features and liver injury and reversed the HFD-decreased abundance of Porphyromonadaceae_unclassified and Prevotella genus, while boosting the abundance of Lactobacillus genus. Metabolomics data revealed that VD intake increased tyrosine metabolism, tryptophan metabolism, arginine biosynthesis, and sphingolipid metabolism. Integrated analysis of the gut microbiota and metabolism suggested that genus Prevotella positively correlated with tryptophan metabolism and sphingolipid metabolism as well as certain metabolites such as serotonin, melatonin, tryptamine, L-arginine, and 3-dehydrosphinganine. This comprehensive integrated microbiota and metabolomic analysis demonstrated that VD supplementation could be a potential intervention for anti-NAFLD by targeting the specific microbiota and metabolism.

Probiotic Lactobacillus plantarum ATCC14917 has been reported to alleviate the progression of atherosclerotic lesion formation and improve inflammation and oxidative stress in mice (Hassan et al., 2020). However, whether L. plantarum ATCC14917 could ameliorate NAFLD has not been elucidated. In this study, Wen et al. found that both low and high doses of L. plantarum ATCC14917 could alleviate NAFLD features and improve serum lipid metabolism as well as regulate gut microbial composition and structure. Additionally, the activity of superoxide dismutase and the content of GSH-Px were increased, but malondialdehyde content was reduced in the liver compared with the HFD group. With L. plantarum ATCC14917 intervention, the levels of these inflammatory cytokines were significantly reversed in the treatment groups, accompanied by an altered TLR4/NFκB signaling pathway. These results revealed that L. plantarum ATCC14917 can be an alternative therapy for the intervention of NAFLD.

Obesity has become a global health and socioeconomic problem, while Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the two most used strategies for weight loss. In this study, Yang et al. performed a comprehensive analysis and found that SG surgery induced modest microbial alteration compared to RYGB. RYGB operation significantly decreased Firmicutes/Bacteroides (F/B) ratio and increased the proportion of Escherichia, Bacteroides, and Akkermansia genera, which might suppress phytosphingosine the sphingosine metabolisms. and Overall, the study revealed that the beneficial effect of RYGB in weight loss might be through the regulation of bacterial-metabolite crosstalk.

Dietary-dependent recovery of host metabolism from antibiotic exposure has been explored previously (Li et al., 2021). Endika et al. investigated two prebiotics, namely 2'-fucosyllactose (2'-FL) and galacto-oligosaccharides (GOS), on the recovery of 1- and 3-month-old infant gut microbiota to amoxicillin-/clavulanateinduced changes in microbiota composition and activity. In the *in vitro* colon model, amoxicillin/clavulanate time dependently caused deviations in microbiota composition. Supplementation of 2'-FL in the colon model of 1-month-old infant gut microbiota promoted the recovery of microbiota with mixed taxa and restored the production of propionate and butyrate. However, GOS supplementation in the colon model using the 3-month-old infant gut microbiota promoted the recovery of *Bifidobacteria*, dominated microbiota, and increased the production of acetate and butyrate. These findings suggested that prebiotics, such as 2'-FL and GOS supplementation, could have added value in promoting the recovery of microbiota in the gut of antibiotic-treated infants.

Seasonal differences in the gut microbiota composition have been reported (Huang and Liao, 2021; Marsh et al., 2022). However, the mechanism underlying these differences remains unclear. Li et al. analyzed the gut microbiota changes and intestinal water metabolism under four seasons that were simulated using the balanced temperature and humidity control system and found that seasonal changes could affect the concentration of colonic 5-hydroxytryptamine and vasoactive intestinal peptide in rats, accompanied by altered contents of AQPs through cAMP/PKA pathway resulting in the alteration of the intestinal water metabolism. These results uncovered the mechanism of how seasonal factors affect the level of intestinal water metabolism that leads to seasonal differences in gut microbiota.

Nutritional and dietary supplements are getting more and more attention for their health effect in regulating lipid and glucose metabolism. In addition to metabolic regulation, Han et al. summarized dietary and microbial nutrients as well as their roles and applications for prolonging reproductive lifespan in female patients. This review discussed the effects and mechanisms of dietary nutrients and microbe-related nutritional substances (including carbohydrates, fat and lipoprotein, protein and polypeptide, vitamins, phytoestrogens, probiotics, prebiotics, and synbiotics) on improving premature ovarian insufficiency, providing important information for the better and healthier life of female individuals.

Overall, these studies provide important insights into the effects of various dietary nutrients, probiotics, and prebiotics on host health by regulating gut microbiota composition and function as well as metabolites. However, further research is needed to fully understand the causal relationship between health improvement and gut microbiota changes upon dietary intervention. Additionally, germ-free mice or fecal microbiota transplantation should be considered to explore the role of gut microbiota in regulating host metabolism after dietary or microbial metabolites intervention. Together, these studies contribute to our understanding of dietary supplementation on host health through gut microbiota and provide important insights into the study of their beneficial effect mechanism.

Author contributions

LShe: Writing—original draft, Writing—review and editing. XZ: Writing—review and editing. LShi: Writing—review and editing. PJ: Writing—review and editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Cani, P. D., Van Hul, M., Lefort, C., Depommier, C., Rastelli, M., and Everard, A. (2019). Microbial regulation of organismal energy homeostasis. *Nat. Metab.* 1, 34–46. doi: 10.1038/s42255-018-0017-4

de Vos, W. M., Tilg, H., Van Hul, M., and Cani, P. D. (2022). Gut microbiome and health: mechanistic insights. *Gut* 71, 1020–1032. doi: 10.1136/gutjnl-2021-3 26789

Hassan, A., Din, A. U., Zhu, Y., Zhang, K., Li, T., Wang, Y., et al. (2020). Anti-atherosclerotic effects of Lactobacillus plantarum ATCC 14917 in ApoE-/- mice through modulation of proinflammatory cytokines and oxidative stress. *Appl. Microbiol. Biotechnol.* 104, 6337–6350. doi: 10.1007/s00253-020-10693-x

Huang, C., and Liao, W. (2021). Seasonal variation in gut microbiota related to diet in fejervarya limnocharis. *Animals.* 11, 1393. doi: 10.3390/ani11051393

Li, B., Qiu, H., Zheng, N., Wu, G., Gu, Y., Zhong, J., et al. (2021). Integrated metagenomic and transcriptomic analyses reveal the dietary dependent recovery

of host metabolism from antibiotic exposure. Front. Cell Dev. Biol. 9, 680174. doi: 10.3389/fcell.2021.680174

Li, Q., Liu, W., Zhang, H., Chen, C., Liu, R., Hou, H., et al. (2023). α-D-1,3-glucan from Radix Puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites. *Carbohydr. Polym.* 299, 120197. doi: 10.1016/j.carbpol.2022.120197

Marsh, K. J., Raulo, A. M., Brouard, M., Troitsky, T., English, H. M., Allen, B., et al. (2022). Synchronous seasonality in the gut microbiota of wild mouse populations. *Front. Microbiol.* 13, 809735. doi: 10.3389/fmicb.2022.809735

Sung, M. M., Kim, T. T., Denou, E., Soltys, C.-L. M., Hamza, S. M., Byrne, N. J., et al. (2017). Improved glucose homeostasis in obese mice treated with resveratrol is associated with alterations in the gut microbiome. *Diabetes* 66, 418–425. doi: 10.2337/db16-0680

Wu, J., Wang, K., Wang, X., Pang, Y., and Jiang, C. (2021). The role of the gut microbiome and its metabolites in metabolic diseases. *Protein Cell* 12, 360–373. doi: 10.1007/s13238-020-00814-7